Organon & Co. (OGN) Stock

Healthcare · Drug Manufacturers - General · Member of Other US Stocks

Organon & Co. (OGN) closed at USD 13.74 on 2026-10-14, a change of +108 % over the past year, with a market capitalization of USD 3.61B.

Organon & Co. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Organon & Co. key figures

Previous close

USD 13.74 (2026-10-14)

1-year change

+108 %

Market cap

USD 3.61B

Enterprise value

USD 11.03B

P/E ratio (trailing)

17.64

P/E ratio (forward)

3.81

EPS (trailing)

0.78

EPS (forward)

3.62

PEG ratio

n/a

Price to book

3.59

Revenue growth

-2.3 %

Earnings growth

-28.3 %

Dividend per share (trailing)

0.08

Short ratio

7.09

Employees

10,000

Analyst consensus (third-party)

hold

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Organon & Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Organon & Co. and compare it with other stocks.